Michal Rose, MD

• Amer Zeidan
• Amy Justice
• Cary Gross
• Cynthia Brandt
• Daniel Federman
• Ellice Wong
• Hari Deshpande
• Herta Chao
• Jeffrey Kravetz
• John Concato
• Kathleen Akgün
• Ling Han
• Lori Bastian
• Natalia Neparidze
• Roxanne Wadia
• Tamar Taddei

Health Services Research; Hematology; Medical Oncology; Veterans

Health Care Management

• Multiple Annual Low Dose CT Scans Needed to Detect Malignancy: Number Needed to Scan 蠅4Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Akgun K, Cain H, Rose M. Multiple Annual Low Dose CT Scans Needed to Detect Malignancy: Number Needed to Scan 蠅4. 2023, a2732-a2732. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2732.
• Disparities in Lung Cancer Screening in a Sample of VeteransBernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Rose M, Cain H, Akgun K. Disparities in Lung Cancer Screening in a Sample of Veterans. 2023, a2733-a2733. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2733.
• Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer ScreeningBernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Rose M, Akgun K, Cain H. Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening. 2023, a2734-a2734. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2734.
• Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and TreatmentsRose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments. The Cancer Journal 2023, 29: 109-110. PMID: 37195765, DOI: 10.1097/ppo.0000000000000663.
• Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience.Xiang J, Roy A, Summers C, Delvy M, O'Donovan J, Christensen J, Perry L, Connery D, Rose M, Chao H. Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience. Journal Of Clinical Oncology 2021, 39: 79-79. DOI: 10.1200/jco.2020.39.28_suppl.79.
• "Lost to Follow-Up?" Barriers to Lung Cancer Screening Adherence in US VeteransBade B, DeRycke E, Kunitomo Y, Lerz K, Skanderson M, Rose M, DiDomenico P, Conti M, Taylor C, Crothers K, Federman D, Haskell S, Bean-Mayberry B, Brandt C, Bastian L, Akgun K, Cain H. "Lost to Follow-Up?" Barriers to Lung Cancer Screening Adherence in US Veterans. 2021, a4775-a4775. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4775.
• Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer.Presley C, Kaur K, Han L, Soulos P, Zhu W, Corneau E, O'Leary J, Chao H, Shamas T, Rose M, Lorenz K, Levy C, Mor V, Gross C. Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer. Journal Of Clinical Oncology 2020, 38: 12025-12025. DOI: 10.1200/jco.2020.38.15_suppl.12025.
• Comorbidities in Veterans Undergoing Lung Cancer ScreeningBade B, DeRycke E, Lerz K, Skanderson M, Rose M, Obando A, Taylor C, Crothers K, Haskell S, Bean-Mayberry B, Brandt C, Bastian L, Akgun K, Cain H. Comorbidities in Veterans Undergoing Lung Cancer Screening. 2020, a5924-a5924. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5924.
• Multicenter phase II trial of RRx-001 in previously treated SCLC.Morgensztern D, Rose M, Morris J, Ma P, Brzezniak C, Zeman K, Padmanabhan A, Hirth J, Spira A, Wong E, Padda S, Waqar S. Multicenter phase II trial of RRx-001 in previously treated SCLC. Journal Of Clinical Oncology 2019, 37: e20104-e20104. DOI: 10.1200/jco.2019.37.15_suppl.e20104.
• Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple MyelomaGiri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma. Blood 2018, 132: 3162. DOI: 10.1182/blood-2018-99-115633.
• QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.Padda S, Brzezniak C, Waqar S, Wakelee H, Ma P, Rose M, Reid T, Spira A, Wong E, Zeman K, Oronsky B, Abrouk N, Morgensztern D. QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Journal Of Clinical Oncology 2018, 36: e20575-e20575. DOI: 10.1200/jco.2018.36.15_suppl.e20575.
• Concurrent Care and Aggressive End-of-Life Lung Cancer CarePresley C, Han L, O'leary J, Chao H, Shamas T, Kerin A, Rose M, Gross C. Concurrent Care and Aggressive End-of-Life Lung Cancer Care. Journal Of Thoracic Oncology 2017, 12: s1545. DOI: 10.1016/j.jtho.2017.06.058.
• Gleason grade in HIV+ versus uninfected prostate cancer patients in the Veterans Aging Cohort study.Wadia R, Park L, Brandt C, Rose M, Chao H, Gibert C, Rimland D, Rodriguez-Barradas M, Justice A. Gleason grade in HIV+ versus uninfected prostate cancer patients in the Veterans Aging Cohort study. Journal Of Clinical Oncology 2016, 34: e16560-e16560. DOI: 10.1200/jco.2016.34.15_suppl.e16560.
• Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient SatisfactionNeparidze N, Cecchini M, Wong E, Rose M. Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction. Blood 2014, 124: 4857. DOI: 10.1182/blood.v124.21.4857.4857.
• Effect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS).Wadia R, Yao X, Deng Y, Li J, Maron S, Connery D, Gunduz-Bruce H, Rose M. Effect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS). Journal Of Clinical Oncology 2014, 32: 6542-6542. DOI: 10.1200/jco.2014.32.15_suppl.6542.
• EMR-linked cancer tracker facilitates lung and liver cancer care.Taddei T, Hunnibell L, DeLorenzo A, Rosa M, Connery D, Vogel D, Garla V, Taylor C, Rose M. EMR-linked cancer tracker facilitates lung and liver cancer care. Journal Of Clinical Oncology 2012, 30: 77-77. DOI: 10.1200/jco.2012.30.34_suppl.77.
• Timeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center.Alsamarai S, Chao H, Yao X, Deng Y, Rose M. Timeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center. Journal Of Clinical Oncology 2012, 30: 6033-6033. DOI: 10.1200/jco.2012.30.15_suppl.6033.
• Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study.Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Grady T, Klein C, Mehta P, Hayes T, Roodman G, Lichtenstein A. Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. Journal Of Clinical Oncology 2011, 29: 8074-8074. DOI: 10.1200/jco.2011.29.15_suppl.8074.
• Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of TherapyChao H, Mayer T, Concato J, Rose M, Uchio E, Kelly K. Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy. Journal Of Investigative Medicine 2010, 58: 566. DOI: 10.2310/jim.0b013e3181cf9002.
• Chapter 49 Disorders of Red Blood CellsRose M, Berliner N. Chapter 49 Disorders of Red Blood Cells. 2010, 520-532. DOI: 10.1016/b978-1-4160-6109-0.00049-6.
• Chapter 50 Clinical Disorders of NeutrophilsRose M, Berliner N. Chapter 50 Clinical Disorders of Neutrophils. 2010, 533-538. DOI: 10.1016/b978-1-4160-6109-0.00050-2.
• Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC)Galper S, Deshpande H, Rose M, Decker R. Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). Journal Of Clinical Oncology 2009, 27: e17030-e17030. DOI: 10.1200/jco.2009.27.15_suppl.e17030.